FDA Biologics (BLA & Biosimilars)Original article
Influenza Vaccine Composition for the 2026-2027 U.S. Influenza Season
Influenza VaccineNeutral
AI Analysis
Summary
FDA's VRBPAC convened on March 12, 2026, to recommend influenza virus strains for the 2026-2027 U.S. influenza vaccine composition. This is a routine annual regulatory process for seasonal influenza vaccine development.
Outcome Details
VRBPAC meeting to discuss influenza vaccine composition recommendations
Importance:3/10
Sentiment:
0.00
influenza vaccineVRBPACvaccine compositionFDA advisory committee
Read the original article
Published by FDA Biologics (BLA & Biosimilars) on September 3, 2026 1:15 PM